The Era of Vaccines: Advancing Tumor Immunology and Immunotherapy
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: 31 January 2026 | Viewed by 113
Special Issue Editors
Interests: designing novel therapeutic strategy to overcome therapy resistance in different types of cancers; exploring the molecular mechanism of therapeutic resistance in gastrointestinal cancers
Special Issues, Collections and Topics in MDPI journals
Interests: cardiovascular disease; human disease; physiology and cell biology, immunotherapy; drug discovery; molecular biology; genetic engineering
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We invite you to submit to our Special Issue titled “The Era of Vaccines: Advancing Tumor Immunology and Immunotherapy”. The complex interactions between the immune system and cancer have become a vital area of study in oncology, leading to significant advancements in tumor immunology and immunotherapy. We seek articles that explore the mechanisms that regulate immune responses within the tumor microenvironment, innovative immunotherapeutic treatments, and translational methods to improve cancer treatment outcomes. The Special Issue will include advancements in neoantigen-based vaccines, dendritic cell vaccines, mRNA vaccines, peptide-based approaches, and combination therapies. We welcome research articles, reviews, and novel methodologies that cover key topics such as cancer vaccines and immunotherapy, tumor immune evasion, immune checkpoint blockade therapy, mechanisms of resistance, CAR-T, T and NK cell therapies, biomarkers, and immunotherapy.
Dr. Surendra Shukla
Dr. Vinay Kumar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunotherapy
- tumor microenvironment
- immune editing
- immune checkpoints, CAR-T and NK therapy
- biomarkers for immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
